Finance

Novo Nordisk Ireland expansion sharpens Wegovy supply, edges Lilly

Novo Nordisk is investing 432 million euros to expand its Athlone, Ireland facility to boost Wegovy pill production, with completion planned for 2027–2028 as demand outside the U.S. grows. The move tightens Novo’s supply position against Eli Lilly while signaling a deeper push into oral GLP-1 therapies.

📅 March 02, 2026
⏱️ 2 min read
Novo Nordisk Ireland expansion sharpens Wegovy supply, edges Lilly

Key Takeaways

  • Invest 432 million euros to expand Athlone facility to increase Wegovy pill production.
  • Expansion targets international demand with a 2027–2028 completion timeline.
  • Novo stock fell about 1.2% to a fresh 52-week low after the news.
  • EMA review for oral Wegovy with potential year-end EU approval; regulatory timeline uncertain.
  • Lilly expected to launch forglipron in Q2, potentially shifting the competitive landscape.

People Involved

  • Kasper Bødker Mejlvang Novo executive vice president, supply
  • Henrik Hallengreen Laustsen Analyst at Jyske Bank
  • Søren Løntoft Hansen Analyst at Sydbank

Entities Involved

  • Novo Nordisk A/S Pharmaceutical company
  • Eli Lilly and Company Pharmaceutical company
  • Wegovy Oral GLP-1 obesity therapy product by Novo Nordisk

MarketMoodz Analysis

The Ireland expansion strengthens Novo Nordisk’s ability to meet international Wegovy demand, potentially supporting margins if global uptake remains robust and supply risk declines. The project also raises Novo’s competitive bar against Eli Lilly as Lilly races to bring rival obesity/metabolic drugs to market.

Historically, Novo’s GLP-1 program benefited from first‑mover advantages but faced supply constraints and intensified competition from Lilly. The stock has retraced from mid‑2024 highs, reflecting execution and regulatory risk as the sector pivots toward oral therapies and EU approvals.

Watch for: (1) EMA decision on the oral Wegovy timeline, (2) progress and price dynamics of Lilly’s forglipron, (3) actual capacity added by Athlone through 2027–2028, and (4) global uptake in Wegovy’s new oral form beyond the U.S.

Source: Original Article

Get AI-Powered Market Insights

Stay ahead of market-moving events with our real-time analysis and stock ratings.

Start Your Free Trial